GT Biopharma, Inc. (GTBP)
6.68
+0.72
(+12.08%)
USD |
NASDAQ |
Oct 09, 16:00
6.79
+0.11
(+1.65%)
After-Hours: 20:00
GT Biopharma Enterprise Value : 6.883M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 6.883M |
| October 08, 2026 | 5.596M |
| October 07, 2026 | 6.025M |
| October 06, 2026 | 6.329M |
| October 05, 2026 | 5.954M |
| October 02, 2026 | 5.846M |
| October 01, 2026 | 6.025M |
| September 30, 2026 | 6.508M |
| September 29, 2026 | 7.231M |
| September 28, 2026 | 7.097M |
| September 25, 2026 | 7.258M |
| September 24, 2026 | 7.151M |
| September 23, 2026 | 7.633M |
| September 22, 2026 | 7.776M |
| September 21, 2026 | 7.776M |
| September 18, 2026 | 7.740M |
| September 17, 2026 | 8.330M |
| September 16, 2026 | 8.902M |
| September 15, 2026 | 11.03M |
| September 14, 2026 | 15.73M |
| September 11, 2026 | 10.33M |
| September 10, 2026 | 5.989M |
| September 09, 2026 | 5.632M |
| September 08, 2026 | 4.309M |
| September 04, 2026 | 5.712M |
| Date | Value |
|---|---|
| September 03, 2026 | 6.222M |
| September 02, 2026 | 7.589M |
| September 01, 2026 | 7.852M |
| August 31, 2026 | 7.723M |
| August 28, 2026 | 8.348M |
| August 27, 2026 | 8.428M |
| August 26, 2026 | 7.906M |
| August 25, 2026 | 8.335M |
| August 24, 2026 | 8.607M |
| August 21, 2026 | 7.839M |
| August 20, 2026 | 7.544M |
| August 19, 2026 | 7.763M |
| August 18, 2026 | 7.249M |
| August 17, 2026 | 7.678M |
| August 14, 2026 | 8.169M |
| August 13, 2026 | 8.232M |
| August 12, 2026 | 8.442M |
| August 11, 2026 | 8.920M |
| August 10, 2026 | 9.268M |
| August 07, 2026 | 9.246M |
| August 06, 2026 | 8.393M |
| August 05, 2026 | 9.130M |
| August 04, 2026 | 9.514M |
| August 03, 2026 | 8.732M |
| July 31, 2026 | 8.058M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
| Vericel Corp. | 1.984B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.518M |
| Total Expenses (Quarterly) | 4.518M |
| EPS Diluted (Quarterly) | -2.957 |
| Earnings Yield | -1.35K% |
| Normalized Earnings Yield | -2579.14 |